Hormone receptor-positive, HER2-negative breast cancer (HR+/HER2- BC) represents a significant fraction of all breast cancer diagnoses. While conventional treatment with endocrine therapy (ET) and CDK4/6 inhibitors has improved clinical outcomes, the developmentRead More…
Cancer has become one of the leading causes of disease-related death globally. According to updated global cancer statistics from the International Agency for Research on Cancer (IARC), there were nearly 20 millionRead More…
In recent years, a new class of cancer therapies known as antibody-drug conjugates (ADCs) has been gaining significant traction. These innovative therapies represent a smarter, more targeted approach to cancer treatment, combiningRead More…
Today, when talking about cancer color change, pancreatic cancer can be said to be a “tough role” in cancer. It is highly malignant and ranks seventh in the world. Among them, pancreaticRead More…
“If the first generation of ADCs were rifles, the new wave is starting to look like programmable cruise missiles.” —Anonymous medicinal chemist at a recent Keystone symposium In the decade since brentuximabRead More…
The field of oncology has witnessed a paradigm shift in recent years with the rise of antibody-drug conjugates (ADCs). These sophisticated therapies combine the precision of monoclonal antibodies with the cytotoxic powerRead More…
In the ever-evolving landscape of oncology, the integration of targeted therapies and immunotherapy has emerged as a transformative strategy, particularly in breast cancer. Antibody-drug conjugates (ADCs), celebrated for their precision in deliveringRead More…
Antibody-Drug Conjugates (ADCs) have revolutionized cancer therapy by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. These “guided missiles” selectively deliver payloads to tumor cells, minimizing damage toRead More…
Antibody-Oligonucleotide Conjugates (AOCs) represent a new medical frontier which emerged through the integration of antibody technology with nucleic acid therapies. These hybrid molecules which integrate monoclonal antibodies precision with oligonucleotides gene-editing ability areRead More…
The field of antibody-drug conjugates (ADCs) is experiencing a major transformation due to the development of bispecific ADCs (BsADCs) that merge the dual-targeting functionality of bispecific antibodies (BsAbs) with the cell-killing powerRead More…